Difference between revisions of "Vinblastine (Velban)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "Lexicomp") |
||
| (13 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[ | + | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-091-10%20VIN%2010MG/5539009110 Vinblastine (Velban) package insert]</ref><ref>[[:File:Vinblastine.pdf|Vinblastine (Velban) package insert (locally hosted backup)]]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/Vinblastine.aspx Vinblastine (Velban) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Vinblastine.aspx Vinblastine (Velban) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/vinblastine-patient-drug-information Vinblastine (Velban) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vinblastine-patient-drug-information Vinblastine (Velban) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/vinblastine-patient-drug-information Vinblastine (Velban) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vinblastine-patient-drug-information Vinblastine (Velban) patient drug information (UpToDate)]</ref> | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | |||
*Lymphoma | *Lymphoma | ||
**[[Diffuse large B-cell lymphoma]] | **[[Diffuse large B-cell lymphoma]] | ||
**[[HIV-associated lymphoma]] | **[[HIV-associated lymphoma]] | ||
| − | **[[Hodgkin lymphoma]] | + | **[[Classical Hodgkin lymphoma]] |
**[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | **[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
*[[Kaposi sarcoma]] | *[[Kaposi sarcoma]] | ||
| Line 23: | Line 22: | ||
**[[Desmoid tumors]] | **[[Desmoid tumors]] | ||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
| − | + | *[[Urothelial carcinoma]] | |
| + | **[[Bladder cancer]] | ||
==Diseases for which it was used== | ==Diseases for which it was used== | ||
*[[Breast cancer - historical|Breast cancer]] | *[[Breast cancer - historical|Breast cancer]] | ||
| Line 33: | Line 33: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | 11 | + | *1961: Initial approval (unclear details) |
| + | *1965-11-25: Initial approval as Velban | ||
| + | *Uncertain date: Approved for generalized [[Classical Hodgkin lymphoma|Hodgkin's disease]] (Stages III and IV, Ann Arbor modification of Rye staging system). ''(No supporting studies are cited)'' | ||
| + | *Uncertain date: Approved for [[:Category:Non-Hodgkin lymphomas|lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated)]]. ''(No supporting studies are cited)'' | ||
| + | *Uncertain date: Approved for [[Diffuse large B-cell lymphoma|histiocytic lymphoma]]. ''(No supporting studies are cited)'' | ||
| + | *Uncertain date: Approved for [[cutaneous T-cell lymphoma|mycosis fungoides]] (advanced stages). ''(No supporting studies are cited)'' | ||
| + | *Uncertain date: Approved for [[testicular cancer|advanced carcinoma of the testis]]. ''(Based on Loehrer et al. 1988)'' | ||
| + | *Uncertain date: Approved for [[Kaposi sarcoma|Kaposi's sarcoma]]. ''(No supporting studies are cited)'' | ||
| + | *Uncertain date: Approved for Letterer-Siwe disease (histiocytosis X). ''(No supporting studies are cited)'' | ||
| + | *Uncertain date: Approved for [[Gestational trophoblastic neoplasia|choriocarcinoma resistant to other chemotherapeutic agents]]. ''(No supporting studies are cited)'' | ||
| + | *Uncertain date: Approved for [[breast cancer|carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy]]. ''(No supporting studies are cited)'' | ||
==Also known as== | ==Also known as== | ||
| Line 80: | Line 90: | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | [[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | ||
[[Category:Kaposi sarcoma medications]] | [[Category:Kaposi sarcoma medications]] | ||
| Line 86: | Line 96: | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
| + | [[Category:Urothelial carcinoma medications]] | ||
[[Category:Breast cancer medications (historic)]] | [[Category:Breast cancer medications (historic)]] | ||
| Line 94: | Line 105: | ||
[[Category:Small cell lung cancer medications (historic)]] | [[Category:Small cell lung cancer medications (historic)]] | ||
| − | [[Category:FDA approved in | + | [[Category:FDA approved in 1961]] |
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 12:00, 29 June 2024
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Vinblastine (Velban) patient drug information (Chemocare)[3]
- Vinblastine (Velban) patient drug information (UpToDate)[4]
Diseases for which it is used
- Lymphoma
- Kaposi sarcoma
- Langerhans cell histiocytosis
- Non-small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
- Urothelial carcinoma
Diseases for which it was used
- Breast cancer
- Head and neck cancer
- Melanoma
- Prostate cancer
- Renal cell carcinoma
- Small cell lung cancer
History of changes in FDA indication
- 1961: Initial approval (unclear details)
- 1965-11-25: Initial approval as Velban
- Uncertain date: Approved for generalized Hodgkin's disease (Stages III and IV, Ann Arbor modification of Rye staging system). (No supporting studies are cited)
- Uncertain date: Approved for lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated). (No supporting studies are cited)
- Uncertain date: Approved for histiocytic lymphoma. (No supporting studies are cited)
- Uncertain date: Approved for mycosis fungoides (advanced stages). (No supporting studies are cited)
- Uncertain date: Approved for advanced carcinoma of the testis. (Based on Loehrer et al. 1988)
- Uncertain date: Approved for Kaposi's sarcoma. (No supporting studies are cited)
- Uncertain date: Approved for Letterer-Siwe disease (histiocytosis X). (No supporting studies are cited)
- Uncertain date: Approved for choriocarcinoma resistant to other chemotherapeutic agents. (No supporting studies are cited)
- Uncertain date: Approved for carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy. (No supporting studies are cited)
Also known as
- Generic names: chlorhexamide, vinblastine sulfate, vinblastine sulphate, vincaleukoblastine, VLB
- Brand names:
| Synonyms | ||||
|---|---|---|---|---|
| Alkaban-AQ | Blastovin | Cellblastin | Cytoblastine | Erbablas |
| Exal | Faulblastina | Lemblastine | Periblastine | Rabinefil |
| Velban | Velbastine | Velbe | Vinblasin | Vinblastin |
| Vinblastina | ||||
References
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Microtubule inhibitors
- Vinca alkaloids
- Bladder cancer medications
- Desmoid tumor medications
- Diffuse large B-cell lymphoma medications
- HIV-associated lymphoma medications
- Classical Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Kaposi sarcoma medications
- Langerhans cell histiocytosis medications
- Non-small cell lung cancer medications
- Testicular cancer medications
- Urothelial carcinoma medications
- Breast cancer medications (historic)
- Head and neck cancer medications (historic)
- Melanoma medications (historic)
- Prostate cancer medications (historic)
- Renal cell carcinoma medications (historic)
- Small cell lung cancer medications (historic)
- FDA approved in 1961
- WHO Essential Cancer Medicine